Ritu Gupta

Special Counsel
Full contact info

Experience

Cooley Advises Lantheus on Concurrent PIPE Investment, Partnering Transaction, Asset Sale With Perspective Therapeutics

January 9, 2024

Cooley advised Lantheus Holdings, a top publicly traded radiopharmaceutical-focused company, on a concurrent private investment in public equity (PIPE) transaction, partnering transaction and asset sale with Perspective Therapeutics.

Read more

Related contacts

Div Gupta
Partner, New York
Geoffrey Spolyar
Partner, Boston
Bill Roegge
Partner, New York
Ritu Gupta
Special Counsel, New York
Zachary Sonenshine
Associate, New York
Valerie Sapozhnikova
Associate, Los Angeles Downtown
Eileen Marshall
Partner, Washington, DC

Related Practices & Industries

Tentarix Biotherapeutics Announces Three Collaborations, Plus Acquisition Options With Gilead Sciences

August 15, 2023

Cooley advised Tentarix Biotherapeutics and three of its subsidiaries on three multiyear collaborations with Gilead Sciences.

Read more

Related contacts

Charity Williams
Partner, San Diego
Rama Padmanabhan
Partner, San Diego
Ritu Gupta
Special Counsel, New York
Jameson Davis
Associate, Palo Alto
Lindsey O'Crump
Associate, Washington, DC
Joshua C. Allen
Associate, Chicago
Todd Gluth
Partner, San Diego
Jeffrey J. Tolin
Partner, New York
Amanda Pacheco
Associate, Palo Alto
Howard Morse
Partner, Washington, DC
Rubin Waranch
Associate, Washington, DC
Lei Shen
Partner, Chicago
Gary Warren Hunt III
Associate, Washington, DC
Kristin R. Marshall
Associate, Washington, DC
Ross Eberly
Partner, Los Angeles Santa Monica
Tom Coll
Partner, San Diego
Edmond Lay
Associate, San Diego
Michael Weinstein
Associate, San Diego
Max Levinbook
Associate, San Diego
Barbara Mirza
Partner, Los Angeles Santa Monica
Natasha Leskovsek
Of Counsel, Washington, DC

Related Practices & Industries

Therachon Sells to Pfizer for up to $810 Million

May 21, 2019

Cooley advised Therachon Holding, a clinical-stage biotechnology company focused on rare diseases, in its agreement to sell to Pfizer, an innovative biopharmaceutical company discovering, developing and providing medicines, vaccines and consumer healthcare products, for up to $810 million. Partners Ryan Sansom and Michal Berkner led the Cooley team. 

Related contacts

Ryan Sansom
Partner, Boston
Barbara Mirza
Partner, Los Angeles Santa Monica
Ivor Elrifi
Partner, New York
Geoffrey Spolyar
Partner, Boston
Xander Lee
Partner, Los Angeles Santa Monica
Kenneth Krisko
Partner, Reston
Brandon W. Fenn
Partner, New York
Megan Browdie
Partner, Washington, DC
Ritu Gupta
Special Counsel, New York
Stephanie Parker Palmer
Special Counsel, Reston

Related Practices & Industries

Kineta Announces Collaboration with Pfizer

December 18, 2018

Cooley advised Kineta Immuno-Oncology (KIO), a subsidiary of clinical-stage biotechnology company Kineta, in its strategic research collaboration with Pfizer to develop RIG-I agonist immunotherapies for the treatment of cancer. Under the terms of the agreement, KIO will receive a $15 million upfront payment and will be eligible to receive up to $505 million in potential research, development and sales milestone payments. Additionally, KIO is eligible to receive tiered royalties on net sales.

Related contacts

Marya Postner
Partner, Palo Alto
Ritu Gupta
Special Counsel, New York

Related Practices & Industries